Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 0.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 585,992 shares of the company’s stock after selling 2,900 shares during the period. Rhumbline Advisers owned about 0.15% of Moderna worth $69,586,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. CIBC Asset Management Inc grew its stake in shares of Moderna by 1.2% during the 2nd quarter. CIBC Asset Management Inc now owns 107,028 shares of the company’s stock worth $12,710,000 after purchasing an additional 1,257 shares during the period. Natixis Advisors LLC grew its position in Moderna by 131.3% during the second quarter. Natixis Advisors LLC now owns 70,510 shares of the company’s stock worth $8,373,000 after buying an additional 40,021 shares during the period. Claro Advisors LLC increased its holdings in Moderna by 2.0% in the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after buying an additional 108 shares in the last quarter. Interchange Capital Partners LLC acquired a new stake in shares of Moderna during the 2nd quarter valued at approximately $212,000. Finally, Avaii Wealth Management LLC purchased a new stake in shares of Moderna during the 2nd quarter worth approximately $2,652,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 5,178 shares of the stock in a transaction on Monday, June 10th. The shares were sold at an average price of $148.09, for a total value of $766,810.02. Following the completion of the sale, the insider now owns 15,947 shares of the company’s stock, valued at $2,361,591.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total value of $2,072,400.00. Following the completion of the sale, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Shannon Thyme Klinger sold 5,178 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $148.09, for a total transaction of $766,810.02. Following the transaction, the insider now directly owns 15,947 shares in the company, valued at $2,361,591.23. The disclosure for this sale can be found here. Insiders have sold a total of 316,168 shares of company stock valued at $44,094,621 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Down 0.6 %

Shares of NASDAQ MRNA opened at $72.49 on Thursday. The stock has a market capitalization of $27.78 billion, a PE ratio of -4.63 and a beta of 1.67. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average of $102.13 and a 200-day moving average of $112.97. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue was down 29.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.62) earnings per share. On average, analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Royal Bank of Canada downgraded Moderna from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $125.00 to $90.00 in a research report on Monday, August 5th. Oppenheimer raised their target price on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and reduced their price target for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Finally, HSBC raised Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price on the stock in a research note on Wednesday, August 28th. Ten investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $123.79.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.